Differential adoption of castration‐resistant prostate cancer treatment across facilities in a national healthcare system

BACKGROUND: Over the past decade, abiraterone and enzalutamide have largely replaced ketoconazole as oral treatments for castration‐resistant prostate cancer (CRPC). We investigated the differential adoption of abiraterone and enzalutamide across facilities in a national healthcare system to underst...

Descripción completa

Detalles Bibliográficos
Autores principales: Caram, Megan E. V., Kumbier, Kyle, Burns, Jennifer, Sparks, Jordan B., Tsao, Phoebe A., Stensland, Kristian D., Washington, Samuel L., Hollenbeck, Brent K., Shahinian, Vahakn, Skolarus, Ted A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067072/
https://www.ncbi.nlm.nih.gov/pubmed/36790037
http://dx.doi.org/10.1002/cam4.5490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067072/
https://www.ncbi.nlm.nih.gov/pubmed/36790037
http://dx.doi.org/10.1002/cam4.5490

Ejemplares similares